Abstract
Diabetes and pre-diabetes are major contributors to cardiovascular mortality and morbidity. Insulin resistance is a key pathophysiological determinant of the metabolic and vascular abnormalities noted in these disorders. Ineffective vascular repair is likely to be an important contributor to the development of endothelial dysfunction, and subsequently atherosclerosis, in patients with diabetes. Beyond the systemic effects of the insulin resistant phenotype, including factors such as dysglycaemia and inflammation, cellular insulin resistance is emerging as an important factor in diabetic vascular disease. Disordered signal transduction via the PI3-kinase/Akt and MAP-kinase cascades is a hallmark of cellular insulin resistance, and such changes have been linked with both endothelial dysfunction and impaired angiogenesis. In this review we highlight the importance of insulin resistance to vascular repair and regeneration, discuss important cross-talk between the intracellular signalling of insulin and key pro-angiogenic molecules, and link these concepts to common patterns of vascular disease.
Keywords: Angiogenesis, diabetes, insulin resistance, insulin-like growth factor-1, progenitor, vascular
Current Vascular Pharmacology
Title:Insulin- and Growth Factor-Resistance Impairs Vascular Regeneration in Diabetes Mellitus
Volume: 10 Issue: 3
Author(s): Richard M. Cubbon, Noman Ali, Anshu Sengupta and Mark T. Kearney
Affiliation:
Keywords: Angiogenesis, diabetes, insulin resistance, insulin-like growth factor-1, progenitor, vascular
Abstract: Diabetes and pre-diabetes are major contributors to cardiovascular mortality and morbidity. Insulin resistance is a key pathophysiological determinant of the metabolic and vascular abnormalities noted in these disorders. Ineffective vascular repair is likely to be an important contributor to the development of endothelial dysfunction, and subsequently atherosclerosis, in patients with diabetes. Beyond the systemic effects of the insulin resistant phenotype, including factors such as dysglycaemia and inflammation, cellular insulin resistance is emerging as an important factor in diabetic vascular disease. Disordered signal transduction via the PI3-kinase/Akt and MAP-kinase cascades is a hallmark of cellular insulin resistance, and such changes have been linked with both endothelial dysfunction and impaired angiogenesis. In this review we highlight the importance of insulin resistance to vascular repair and regeneration, discuss important cross-talk between the intracellular signalling of insulin and key pro-angiogenic molecules, and link these concepts to common patterns of vascular disease.
Export Options
About this article
Cite this article as:
M. Cubbon Richard, Ali Noman, Sengupta Anshu and T. Kearney Mark, Insulin- and Growth Factor-Resistance Impairs Vascular Regeneration in Diabetes Mellitus, Current Vascular Pharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157016112799959305
DOI https://dx.doi.org/10.2174/157016112799959305 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blood Pressure and Vascular Alterations with Growth in Childhood
Current Pharmaceutical Design Endothelial Progenitor Cells: A Vascular Perspective for Inflammatory Rheumatic Disorders
Current Rheumatology Reviews Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome
Current Pharmaceutical Design Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Efficacy and Safety of Corticosteroids’ Administration for Pulmonary Immaturity in Anticipated Preterm Delivery
Current Pharmaceutical Design Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm – What Does the Evidence Show?
Current Vascular Pharmacology Appropriate Antibiotic Prescribing Pattern in Hospitalized Children
Current Drug Safety Anti-Inflammatory Therapy in Uveitis
Recent Patents on Inflammation & Allergy Drug Discovery PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) B Cell Tolerance: Lessons from Transplantation
Current Drug Targets - Cardiovascular & Hematological Disorders Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Homocysteine and Non-Cardiac Vascular Disease
Current Pharmaceutical Design Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design Hypertension in Diabetes: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Susceptibility Genes in Hypertension
Current Pharmaceutical Design HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)